BrainsWay is an industry leader in the field of transcranial magnetic stimulation (TMS). BrainsWayâs flagship Deep TMS technology is a non-invasive, well-tolerated outpatient treatment, clinically proven to treat psychiatric and neurological conditions. BrainsWay has received FDA-clearance for both major depression (MDD) and obsessive compulsive disorder (OCD- De Novo) and is developing more applications outside of the US. The company also has approval in Japan and other Asian countries. BrainsWay continues to push the TMS envelope with multiple clinical studies and further research into novel indications. BrainsWay has an experienced business and development management team, as well as the backing of key scientific opinion leaders. BrainsWay was founded in 2003 and began trading on the NASDAQ in 2019 under the symbol BWAY. Source
No articles found.
Stoke is pioneering a new way to treat the underlying cause of severe genetic dise...
Stoke is pioneering a new way to treat the unde...
SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company focused...
SELLAS Life Sciences Group, Inc. is a late-stag...
American Seniors Association is a seniors' advocacy and membership organization an...
American Seniors Association is a seniors' advo...
Lonza is an integrated solutions provider that creates value along the Healthcare ...
Lonza is an integrated solutions provider that ...
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on deve...
Aptevo Therapeutics Inc. is a clinical-stage bi...
A patient that is diagnosed with cancer today will have a genetic screen on their ...
A patient that is diagnosed with cancer today w...
As a leading manufacturer of medical devices and components, Atrion makes a wide r...
As a leading manufacturer of medical devices an...
Join the National Investor Network and get the latest information with your interests in mind.